Is KMSTF or DIVO a better dividend investment in 2026?

KMSTF currently yields 62.31% with a 5% 5-year dividend growth rate. DIVO yields 6.49% with 5% growth. The better choice depends on your goal: KMSTF offers higher current income.

What is the dividend yield difference between KMSTF and DIVO?

KMSTF has a forward dividend yield of 62.31% ($2.00/share annually). DIVO yields 6.49% ($2.91/share annually). The yield gap is 55.82 percentage points.

Home › Compare › KMSTF vs DIVO

KMSTF vs DIVO: Dividend Comparison 2026

KMSTF yields 62.31% · DIVO yields 6.49%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 KMSTF wins by $698.3K in total portfolio value

INVESTMENT

TIME HORIZON10 years

KMSTF

● Live price

62.31%

Share price

$3.21

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$729.0K

Annual income

$175,361.30

Full KMSTF calculator →

DIVO

● Live price

6.49%

Share price

$44.85

Annual div

$2.91

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.7K

Annual income

$981.68

Full DIVO calculator →

Portfolio growth — KMSTF vs DIVO

📍 KMSTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	KMSTF	DIVO
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, KMSTF + DIVO cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

KMSTF pays

DIVO pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KMSTF

Annual income on $10K today (after 15% tax)

$5,295.95/yr

After 10yr DRIP, annual income (after tax)

$149,057.10/yr

DIVO

Annual income on $10K today (after 15% tax)

$552.00/yr

After 10yr DRIP, annual income (after tax)

$834.43/yr

At 15% tax rate, KMSTF beats the other by $148,222.68/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KMSTF + DIVO for your $10,000?

KMSTF: 50%DIVO: 50%

100% DIVO50/50100% KMSTF

Portfolio after 10yr

$379.9K

Annual income

$88,171.49/yr

Blended yield

23.21%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KMSTF buys

DIVO buys

No recent congressional trades found for KMSTF or DIVO in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricKMSTFDIVO

Forward yield	62.31% ✓	6.49%
Annual dividend / share	$2.00	$2.91 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$729.0K ✓	$30.7K
Annual income after 10y	$175,361.30 ✓	$981.68
Total dividends collected	$608.8K ✓	$8.2K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: KMSTF vs DIVO ($10,000, DRIP)

Year	KMSTF Portfolio	KMSTF Income/yr	DIVO Portfolio	DIVO Income/yr	Gap
1← crossover	$16,931	$6,230.53	$11,349	$649.42	+$5.6K → KMSTF
2	$27,974	$9,858.52	$12,833	$688.83	+$15.1K → KMSTF
3	$45,156	$15,223.51	$14,459	$727.90	+$30.7K → KMSTF
4	$71,283	$22,966.14	$16,238	$766.49	+$55.0K → KMSTF
5	$110,155	$33,882.50	$18,179	$804.47	+$92.0K → KMSTF
6	$166,800	$48,934.07	$20,293	$841.71	+$146.5K → KMSTF
7	$247,726	$69,249.85	$22,591	$878.14	+$225.1K → KMSTF
8	$361,186	$96,119.21	$25,087	$913.65	+$336.1K → KMSTF
9	$517,443	$130,974.20	$27,791	$948.18	+$489.7K → KMSTF
10	$729,026	$175,361.30	$30,718	$981.68	+$698.3K → KMSTF

KMSTF vs DIVO: Complete Analysis 2026

KMSTF — Stock

Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was founded in 2008 and is based in Ness Ziona, Israel.

Full KMSTF Calculator →

DIVO — ETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →

📬

Get this KMSTF vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KMSTF vs SCHD KMSTF vs JEPI KMSTF vs O KMSTF vs KO KMSTF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.